# Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma

> **NCT04119674** · PHASE1,PHASE2 · COMPLETED · sponsor: **Zhejiang Cancer Hospital** · enrollment: 33 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Drug is Anlotinib.
- **DRUG:** Drug is Temozolomide Capsule.
- **RADIATION:** Radiotherapy was initiated 4 to 6 weeks postoperatively.

## Key facts

- **NCT ID:** NCT04119674
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-19
- **Primary completion:** 2022-08-23
- **Final completion:** 2022-08-23
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04119674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04119674, "Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04119674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*